Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health
Believes Slate Possesses Necessary Experience in Capital Allocation, Corporate Governance, Pet Healthcare, Supply Chain Management and Succession Planning
Contends the Upcoming Annual Meeting is the Ideal Moment to Introduce Truly Independent Directors and Start a Boardroom Dialogue Around a Properly Timed CEO Change in 2025
Reminds Shareholders That Elanco's Leadership Has Failed to Deliver Value and Meet its Own Promises Over Every Long-Term Horizon
Urges Shareholders to Review Presentation Regarding the Case for Shareholder-Driven Change Atop Elanco
Ancora Holdings Group, LLC (together with its affiliates, "Ancora" or "we"), which owns approximately 3% of the outstanding common s
